Holen Sie sich die Stockscreener-App
3.26
6.19%
0.19
Handel nachbörslich:
3.28
0.02
+0.61%
Schlusskurs vom Vortag:
$3.07
Offen:
$3.11
24-Stunden-Volumen:
266.94K
Relative Volume:
0.85
Marktkapitalisierung:
$125.78M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-42.05M
KGV:
-1.156
EPS:
-2.82
Netto-Cashflow:
$-35.26M
1W Leistung:
+4.82%
1M Leistung:
+6.89%
6M Leistung:
-25.40%
1J Leistung:
+70.68%
1-Tages-Spanne:
$3.11
$3.33
1-Wochen-Bereich:
$3.01
$3.33
52-Wochen-Spanne:
$1.595
$10.48
Protara Therapeutics Inc Stock (TARA) Company Profile
Firmenname
Protara Therapeutics Inc
Sektor
Branche
Telefon
646-844-0337
Adresse
345 PARK AVENUE SOUTH, NEW YORK, NY
Vergleichen Sie TARA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TARA
Protara Therapeutics Inc
|
3.26 | 118.45M | 0 | -42.05M | -35.26M | -2.82 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.92 | 99.42B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.55 | 58.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.52 | 56.35B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
646.60 | 39.02B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
307.51 | 34.25B | 3.81B | -644.79M | -669.77M | -6.24 |
Protara Therapeutics Inc Stock (TARA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-16 | Eingeleitet | Scotiabank | Sector Outperform |
| 2025-03-14 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-07-10 | Fortgesetzt | Guggenheim | Buy |
| 2021-06-04 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-02-17 | Eingeleitet | Oppenheimer | Outperform |
| 2020-10-19 | Eingeleitet | Cowen | Outperform |
| 2020-07-29 | Eingeleitet | Guggenheim | Buy |
Alle ansehen
Protara Therapeutics Inc Aktie (TARA) Neueste Nachrichten
Protara Therapeutics Inc. recovery potential after sell off2025 Market Overview & Growth Focused Investment Plans - Newser
What’s the recovery path for long term holders of Protara Therapeutics Inc.Weekly Trade Summary & Growth Oriented Trading Recommendations - Newser
Strategies to average down on Protara Therapeutics Inc.Analyst Upgrade & Free High Accuracy Swing Entry Alerts - Newser
Published on: 2025-08-13 04:45:31 - Newser
Tick level data insight on Protara Therapeutics Inc. volatility2025 Earnings Surprises & Capital Efficiency Focused Strategies - Newser
Using RSI to spot recovery in Protara Therapeutics Inc.Market Performance Summary & Consistent Profit Trading Strategies - Newser
Understanding Protara Therapeutics Inc.’s price movementBuy Entry Confirmation Based on Technical Analysis - Newser
Protara Therapeutics Inc. stock volume spike explainedFree AI-Powered Trade Planning with Indicators - Newser
Applying big data sentiment scoring on Protara Therapeutics Inc. [2025 Momentum Check]High Conviction Investment Ideas - Newser
News impact scoring models applied to Protara Therapeutics Inc. [Market Risk Analysis]Capital Protection Trade Alerts - Newser
Protara Therapeutics Reports Q2 2025 Financial Results - MSN
Backtesting results for Protara Therapeutics Inc. trading strategiesWeekly Return Plan for Conservative Traders - Newser
Published on: 2025-08-12 02:18:08 - Newser
Smart tools for monitoring Protara Therapeutics Inc.’s price actionFree Sector Based Breakout Stock Forecast - Newser
Protara Therapeutics Announces Second Quarter 2025 Financial Results and Provides Business Update - GlobeNewswire
Is Protara Therapeutics Inc. in a bullish channelHigh Growth With Low Risk - mustnews.co.kr
Using data filters to optimize entry into Protara Therapeutics Inc.Growth Projection Summary for Long-Term Investors - Newser
Applying big data sentiment scoring on Protara Therapeutics Inc.Free Growth Focused Entry Plan Suggestions - Newser
Protara Therapeutics: Q2 Earnings Snapshot - Greenwich Time
Protara Therapeutics reports Q2 EPS (35c), consensus (38c) - TipRanks
Protara’s Losses Grew But Wall Street’s Still On Board - Finimize
Protara Beats Q2 Loss Estimates - The Motley Fool
Protara Therapeutics Q2 2025 Financial Results and Business Update - TradingView
Protara Therapeutics' Q2 net loss widens - MarketScreener
Protara Therapeutics, Inc. SEC 10-Q Report - TradingView
Protara (TARA) Announces Q2 2025 Results; Press Release Furnished | TARA SEC FilingForm 8-K - Stock Titan
Protara Therapeutics Reveals Strong $146M Cash Position, Multiple Clinical Milestones Coming in Next 6 Months - Stock Titan
Published on: 2025-08-10 02:01:28 - Newser
How Protara Therapeutics Inc. stock performs during market volatilityFree Pattern Alert With ROI Driven Strategy - Newser
Does Protara Therapeutics Inc. fit your quant trading modelFree Entry Alert With Low Drawdown Strategy - Newser
News impact scoring models applied to Protara Therapeutics Inc.Intraday Movement Recap and Chart Summary - Newser
Combining price and volume data for Protara Therapeutics Inc.Neural Network Based Equity Prediction System - Newser
What earnings revisions data tells us about Protara Therapeutics Inc.Free Trade Setups With AI Powered Filters - Newser
How to build a custom watchlist for Protara Therapeutics Inc.Short-Term AI-Based Stock Price Forecast - Newser
Why Protara Therapeutics Inc. stock attracts strong analyst attentionSmart Entry Signals for Active Traders - Newser
What analysts say about Protara Therapeutics Inc. stockCapitalize on momentum stocks before they peak - Jammu Links News
When is Protara Therapeutics Inc. stock expected to show significant growthTransform your portfolio with high-yield stocks - Jammu Links News
How does Protara Therapeutics Inc. compare to its industry peersOutstanding trading profits - Jammu Links News
Should I hold or sell Protara Therapeutics Inc. stock in 2025Capitalize on market momentum for big wins - Jammu Links News
What catalysts could drive Protara Therapeutics Inc. stock higher in 2025Free Consultation - Jammu Links News
What are Protara Therapeutics Inc. company’s key revenue driversMaximize portfolio growth with expert advice - Jammu Links News
What are analysts’ price targets for Protara Therapeutics Inc. in the next 12 monthsPhenomenal returns - Jammu Links News
Finanzdaten der Protara Therapeutics Inc-Aktie (TARA)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):